AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a ...

AbbVie delivered a strong Q3 2025, with adjusted EPS of $1.86 (beating guidance by $0.10) and net revenues of $15.8B, up 8.4% operationally. Management raised full-year revenue and EPS guidance, ...

Johnson & Johnson’s Tremfya edged out AbbVie’s Skyrizi in the December rankings of the top 10 TV drug ad spenders, chalking up $56.4 million to Skyrizi's $42.3 million. (Martin Barraud/iStock/Getty ...

Welcome to the AbbVie First Quarter 2025 Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. As a reminder, this call is being ...

AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...

As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its ...

AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw ...

CEO Robert Michael stated that "AbbVie's business continues to perform above our expectations. We delivered another excellent quarter, including strong financial results, pipeline advancement across ...

AbbVie reported Q1 2025 adjusted EPS of $2.46, $0.10 above guidance, with revenue of $13.3B (+9.8% operationally). Robust growth in SKYRIZI and RINVOQ (+65% combined) offset HUMIRA’s 49.5% decline.